Open-label rusfertide
Phase 3Peptide
Protagonist TherapeuticsOpen-label rusfertide is one of 11 small molecule programs targeting Polycythemia Vera. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Polycythemia Vera
#DrugCompanyPhaseTrials
1Droxia
TTheravia
Approved
BESREMI
PPharmaEssentia
Approved
Jakafi
IncytePhase 3
Ojjaara
GGlaxo Dba Glaxosmithkline
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Trisenox
CCephalon
Approved
Duvyzat
ItalfarmacoPhase 3
Mimrylo
TakedaPhase 3
Bomedemstat
Merck & Co.Phase 2
Open-label rusfertide
Protagonist TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Open-label rusfertide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Phase 3[1]
- Company